MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Virtual Congress 2020 » Parkinsonism, Atypical: PSP, CBD

Meeting: MDS Virtual Congress 2020

18kDa Translocator Protein PET in 4-Repeat Tauopathies – A Cross-Sectional Single Center Study

C. Palleis, J. Sauerbeck, L. Beyer, S. Harris, J. Schmitt, A. Finze, A. Nitschmann, G. Biechele, K. Boetzel, A. Danek, B. Rauchmann, M. Unterrainer, N. Albert, R. Rupprecht, P. Bartenstein, R. Perneczky, C. Haass, J. Levin, G. Hoeglinger, M. Brendel (Munich, Germany)

Can we stage tau pathology in PSP?

G. Kovacs, M. Lukic, D. Irwin, T. Arzberger, G. Respondek, E. Lee, D. Coughlin, A. Giese, M. Grossman, C. Kurz, C. McMillan, E. Gelpi, Y. Compta, J. van Swieten, C. Troakes, S. Al-Sarraj, J. Robinson, S. Roeber, S. Xie, V. Lee, J. Trojanowski, G. Höglinger (Phildelphia, PA, USA)

Chromogranin B in cerebrospinal fluid as a novel biomarker for Progressive supranuclear palsy

H. Takigawa, R. Sakata, T. Inoue-Nishida, H. Kowa, K. Namashima, R. Hanajima (Yonago, Japan)

Clinical features and natural course of corticobasal degeneration and progressive supranuclear palsy presenting as corticobasal syndrome

I. Aiba, M. Yoshida, T. Shimohata, Y. Hayashi, T. Sano, Y. Saito, S. Murayama, K. Hasegawa, Y. Iwasaki, M. Sakai, K. Wakabayashi, T. Komori, K. Nakashima (Nagoya, Japan)

Cognitive Differences Between Men and Women with Progressive Supranuclear Palsy

E. Bayram, J. Jankovic, S. Reich, C. Marras, Y. Bordelon, D. Shprecher, R. Dubinsky, I. Litvan (La Jolla, CA, USA)

Correlations between amantadine usage, gait, and cognition in PSP: a post hoc analysis of the davunetide trial

M. Dale, B. Brumbach, A. Hiller (Portland, OR, USA)

Decline in the midbrain-to-pons ratio over one year can support the differentiation between PSP and IPD

S. Kannenberg, L. Dinkelbach, J. Caspers, A. Moldovan, S. Ferrea, M. Südmeyer, M. Butz, A. Schnitzler, C. Hartmann (Düsseldorf, Germany)

FDG-PET degeneration patterns predict amyloid deposition in Corticobasal Syndrome

J. Parmera, A. Coutinho, A. Neto, C. Ono, M. Aranha, C. Buchpiguel, R. Nitrini, E. Barbosa, S. Brucki (Sao Paulo, Brazil)

Gait initiation in patients with Progressive Supranuclear Palsy: a biomechanical and FDG-PET study

M. Todisco, C. Palmisano, G. Marotta, C. Pacchetti, G. Pezzoli, I. Isaias (Würzburg, Germany)

Glucocerebrosidase activity and atypical parkinsonism: a multi-centre exploratory study

R. Alvarez Velasco, P. Giraldo, P. Irun, L. Vela Desojo, L. Lopez Manzanares, J.M Arbelo González, M. Eimil Ortiz, A. Rojo Sebastian, M. Mata Álvarez-Santullano, I. Martínez Torres, J. Garcia-Caldentey, M. Gómez Gutierrez, C. Estévez-Fraga, J.L López Sendón, G. García Ribas, J.C Martínez Castrillo, A. Alonso-Canovas (Madrid, Spain)

Is brain perfusion a differentiating factor between Parkinson’s Disease (PD) and Progressive Supranuclear Palsy – Parkinsonism Predominant (PSP-P)?

P. Alster, D. Koziorowski, L. Królicki, A. Friedman (Warsaw, Poland)

Key neuropathological features separating corticobasal degeneration from other related disorders

S. Rezvanian, I. Litvan, D. Dickson (La Jolla, CA, USA)

Midbrain/pons area ratio and clinical features predict the prognosis of Progressive Supranuclear Palsy

S-S. Cui, Y-Y. Tan, S.D Chen (Shanghai, China)

MRI evaluation of Progressive Supranuclear Palsy

M. Kamada (Kagawa, Japan)

Niemann-Pick Type C Presenting as Progressive Supranuclear Palsy

J. Kim, G. Lee (Busan, Republic of Korea)

Photophobia and Progressive Supranuclear Palsy

K. Hay, D. Mohanty, Y. Lin, H. Kang, J. Sellers-Gibson, D. Claassen (Nashville, TN, USA)

Progressive supra nuclear palsy phenotype with idiopathic basal ganglia calcification

R. Ramesh, V. Paramanandham, S. Venkatasubramanian, S. Shanmugam (Chennai, India)

Successful treatment of incessant purposeless groaning in Progressive Supranuclear Palsy with Pimozide

M. Matta, A. Panwar, N. Sawal (Chandigarh, India)

The Progressive Supranuclear Palsy Clinical Deficits Scale

G. Respondek, I. Piot, K. Schweyer, M. Stamelou, P. Sckopke, T. Schenk, C. Goetz, T. Stebbins, G. Höglinger (Hannover, Germany)

The severity and distribution of tau pathology distinguish corticobasal degeneration and progressive supranuclear palsy

S. Koga, N. Ghayal, S. Roemer, D. Dickson (Jacksonville, FL, USA)

« View all categories from the MDS Virtual Congress 2020.

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley